Posts Tagged CRO

European CMOs Hit North American Shores

by

As I was preparing for the INTERPHEX trade show in New York next week, I was really struck by the number of European Contract Manufacturing Organizations (CMOs) attending that don’t have North American facilities. There are at least six including CMOs with a strong recent FDA approval track record such as Rottendorf and Pierre Fabre. […]

Learn more

Capturing CRO Opportunities in the Medical Device and Diagnostic Market

by

Contract research organizations (CROs) seeking to capture business in the medical device and diagnostic segment face a unique range of challenges, most prominently the lack of information shared by medical device companies during the development process. There are ways to overcome the obstacles and win contract research business in the growing medical device and diagnostic […]

Learn more

Charles River Acquires WIL Research, May Target CTM Manufacture

by

Charles River Laboratories (CRL) is acquiring preclinical CRO WIL Research Laboratories for $585 million. CRL pegged the acquisition price at a multiple of 12.9x adjusted EBITDA, and will finance the deal with debt. The transaction is expected to close in the second quarter of this year. The acquisition of WIL Research gives CRL additional capacity […]

Learn more

Macro Matters

by

Heightened global uncertainty could slow bio/pharma development activity. Bio/pharmaceutical companies, and the companies that serve them, tend to think they are immune from broader macroeconomic and political developments. As populations age, emerging middle classes expand, and scientific knowledge progresses, research on new drugs and demand for new therapies seem to follow an inexorably upward trend. […]

Learn more

Early Development Services Enjoy Strong First Half

by

Results from the first half of the year highlighted the importance of external fundraising to drive elements of the outsourcing ecosystem. Contract service providers supporting early development, especially those with a strong presence in drug discovery, posted a revenue increase of 18% on a constant currency basis, led by WuXi Apptec and Charles River Laboratories. […]

Learn more

CDMOs Cautiously Address Expansion

by

These are high times for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). A record flood of external financing is flowing into the bio/pharmaceutical industry. Global bio/pharmaceutical companies are outsourcing more of their development activity, and FDA is being especially accommodating. R&D spending is growing, and the clinical development pipeline is really […]

Learn more

Watch for Strategic Changes in Bio/Pharma Purchasing

by

No matter how good the selling environment may be, bio/pharmaceutical companies are powerful buyers. Would you recognize subtle changes in the behavior of your buyers? It can be crucial to stay attuned for these shifts, so you can anticipate and plan for changing times. While most CROs, CMOs and CDMOs are enjoying today’s flourishing selling […]

Learn more

Follow the Money: Viking Therapeutics, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Viking Therapeutics, Inc. is a U.S. public pharmaceutical company that develops therapies for metabolic and endocrine disorders. As reported in the May 7, 2015 issue of the PharmSource […]

Learn more

More Evidence that Size Matters

by

Size has proven to be a major competitive advantage in the clinical contract research organization (CRO) industry, and if that experience is any guide, it presages how the dose CMO industry will evolve as well. The seven largest clinical CROs, six of which are public companies today, accounted for 52% of bio/pharmaceutical industry spending on […]

Learn more